Cardiovascular Diseases

Research at the site focuses on atherosclerotic cardiovascular disease and the impact of elevated lipoprotein (a) on heart health, aiming to evaluate new therapies that may lower cardiovascular risk.

  • Atherosclerotic cardiovascular disease (ASCVD)
  • Elevated lipoprotein (a)
  • Coronary heart disease outcomes

The investigations are part of the broader clinical program at Centro Hospitalar Universitario Do Porto E.P.E., integrating multidisciplinary expertise.

Eye Diseases

Trials target visual impairment caused by retinal vein occlusion, testing whether higher doses of anti‑VEGF agents improve best‑corrected visual acuity and reduce macular swelling.

  • Macular edema secondary to retinal vein occlusion
  • Aflibercept dosing regimens
  • Visual acuity outcomes

Patients receive care within the hospital’s ophthalmology collaborations, ensuring comprehensive monitoring.

Immune System Diseases

The department evaluates innovative treatments for autoimmune conditions such as systemic lupus erythematosus and hidradenitis suppurativa, seeking to improve disease control and quality of life.

  • Systemic lupus erythematosus (SLE)
  • Hidradenitis suppurativa
  • Autoimmune disease activity
  • Upadacitinib therapy

These studies benefit from the hospital’s strong immunology expertise and patient‑centered approach.

Neoplasms

Oncologic research includes advanced lung cancer subtypes, where agents targeting c‑Met overexpression are compared with standard chemotherapy to extend survival.

  • c‑Met high overexpressing non‑small cell lung cancer
  • Extensive‑stage small‑cell lung cancer
  • Combination chemotherapy
  • Targeted antibody‑drug conjugates

Centro Hospitalar Universitario Do Porto’s oncology service provides the clinical infrastructure for these investigations.

Nervous System Diseases

Clinical studies address seizure disorders, assessing novel oral compounds for reduction of primary generalized tonic‑clonic seizures frequency.

  • Primary generalized tonic‑clonic seizures
  • XEN1101 efficacy
  • Seizure frequency reduction
  • Placebo‑controlled design

Neurology specialists collaborate with the oncology unit to ensure rigorous safety monitoring.

Nutritional and Metabolic Diseases

Trials explore weight management in pediatric obesity, evaluating the effect of weekly semaglutide injections combined with lifestyle counseling.

  • Childhood obesity
  • Semaglutide weekly dosing
  • Reduced‑calorie diet
  • Physical activity promotion

The multidisciplinary team at the hospital integrates nutritionists and endocrinologists for comprehensive care.

Skin and Connective Tissue Diseases

Multiple studies investigate severe eczema and alopecia, testing the efficacy of upadacitinib and rocatinlimab to achieve high skin clearance and hair regrowth.

  • Moderate to severe atopic dermatitis
  • Severe alopecia areata
  • Upadacitinib dose‑flexibility
  • Rocatinlimab efficacy

Dermatology experts at the site conduct regular assessments to track therapeutic outcomes.

Immune system processes

Research delves into underlying immune mechanisms, focusing on pathways modulated by Janus kinase inhibition to treat inflammatory skin and systemic diseases.

  • Janus kinase (JAK) pathway
  • Cytokine signaling modulation
  • Inflammatory response assessment
  • Biomarker analysis

These mechanistic studies complement the interventional trials conducted at Centro Hospitalar Universitario Do Porto.